Tiopronin 100mg tablets

BackgroundCystinuria is a rare genetic kidney stone disease, with no cure. Current treatments involve lowering urinary cystine levels and increasing cystine solubility. This systematic review evaluates the available literature regarding non-surgical interventions for cystinuria.MethodsKey electronic databases were searched for studies that described the clinical management of cystinuria with high diuresis, alkalinizing agents and thiol-based drugs that were published between 2000 and 2022. Observational studies were included if they contained clinical investigation with at least one previous or current episode of cystine stones, urine cystine levels > 250 mg/L and patients being managed with urinary dilution, alkalinizing agents or other pharmacological agents. All included studies were assessed for study design, patient characteristics and outcomes. A qualitative and critical analysis was performed whereby study quality was assessed using Methodological Index for Non-Randomized Studies (MINORS). Two authors performed the quality assessment and excluded the studies with a low MINORS score.ResultsFourteen studies met the review inclusion and quality criteria. Of the fourteen studies, two reported treatment using alkalinizing agents, six reported treatment using thiol-based drugs, and six reported combination treatment using alkalinizing agents and thiol-based drugs. These studies indicated that first-line therapies, including high fluid intake and urinary alkalinization, increased urine volume to > 3 L/day and urinary pH > 7.0, and were associated with reduced urinary cystine levels and cystine stone formation. Second-line therapy with cystine-binding thiol drugs, such as tiopronin and D-penicillamine, reduced urinary cystine levels, cystine crystal volume and increased cystine solubility, resulting in decreased cystine stone formation and stone recurrence rate. Further, combined intervention with alkalinizing agents and thiol-based drugs synergistically reduced stone recurrence.ConclusionCystinuria treatment may require a combined approach of high diuresis, alkalinization and pharmacological interventions with regular monitoring of urinary pH, cystine levels, cystine crystal volume and solubility. However, poor adherence to treatment is relatively frequent, hence the pressing urgency for improved therapies and treatments.

Abstract licence: CC BY

Urolithiasis is a multifactorial condition where stone composition is critical in guiding treatment and prevention strategies. Advanced diagnostic techniques, such as infrared spectroscopy, provide precise stone analysis, enabling clinicians to tailor interventions based on specific stone types and associated metabolic abnormalities. Calcium oxalate monohydrate stones often require invasive approaches like percutaneous nephrolithotomy, while uric acid responds well to dissolution therapy. Cystine stones, linked to genetic cystinuria, necessitate lifelong management, including aggressive hydration, urinary alkalinization, and pharmacological treatments such as tiopronin. Stone composition significantly influences treatment decisions and recurrence prevention in urolithiasis. Integrating detailed compositional analysis into clinical practice enables personalized interventions, improving outcomes and reducing recurrence rates. Future research should focus on refining diagnostic techniques and exploring novel therapies to address the metabolic and environmental contributors to stone formation. Adopting a multidisciplinary, patient-centered approach is essential for advancing the management of urolithiasis.

Abstract licence: CC BY